Natural History of Pancreatic Cancer Recurrence Following "Curative" Resection in Athymic Mice

Journal of Surgical Research

Volumn 149, Issue 1, 2008, Pages 57-61

  Torgenson, Marcus J ^a   Shea, Jill E ^a   Firpo, Matthew A ^a   Dai, Qiang ^a   Mulvihill, Sean J ^a   Scaife, Courtney L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

animal model; pancreatic cancer; recurrence; resection

Indexed keywords

RED FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CELL; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; GENETIC TRANSFECTION; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; PANCREATECTOMY; PANCREATIC NEOPLASMS;

EID: 48949088900     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2007.08.024     Document Type: Article

References (22)

1. Bouvet M., Gamagami R.A., Gilpin E.A., et al. Factors influencing survival after resection for periampullary neoplasms. Am J Surg 180 (2000) 13
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
3. Sperti C., Pasquali C., Piccoli A., et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21 (1997) 195
4. Katz M.H., Takimoto S., Spivack D., et al. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 113 (2003) 151
5. Vezeridis M.P., Doremus C.M., Tibbetts L.M., et al. Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse. J Surg Oncol 40 (1989) 261
6. Capella G., Farre L., Villanueva A., et al. Orthotopic models of human pancreatic cancer. Ann NY Acad Sci 880 (1999) 103
7. Haq M., Shafii A., Zervos E.E., et al. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res 60 (2000) 3207
8. Mohammad R.M., Al-Katib A., Pettit G.R., et al. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: Potential application for preclinical studies. Clin Cancer Res 4 (1998) 887
9. Katz M.H., Bouvet M., Takimoto S., et al. Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent orthotopic model of human pancreatic cancer. Cancer Res 64 (2004) 1828
10. Eibl G., and Reber H.A. A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas 31 (2005) 258
11. Lee N.C., Bouvet M., Nardin S., et al. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clin Exp Metast 18 (2000) 379
12. Tepel J., Kruse M.L., Kapischke M., et al. Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology 6 (2006) 240
13. Liu Y., Shu X.-Z., and Prestwich G.D. Tumor engineering: Orthotopic cancer models in mice using cell-loaded, injectable, cross-linked hyaluronan-derived hydrogels. Tissue Eng 13 (2007) 1091
14. Loukopoulos P., Kanetaka K., Takamura M., et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29 (2004) 193
15. Yonezawa S., Byrd J.C., Dahiya R., et al. Differential mucin gene expression in human pancreatic and colon cancer cells. Biochem J 276 (1991) 599
16. Chen W.H., Horoszewicz J.S., Leong S.S., et al. Human pancreatic adenocarcinoma: In vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 18 (1982) 24
17. Yunis A.A., Arimura G.K., and Russin D.J. Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: Sensitivity to asparaginase. Int J Cancer 19 (1977) 128
18. El-Rayes B.F., Ali S., Sarkar F.H., et al. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Therapeut 3 (2004) 1421
19. Hotz H.G., Hines O.J., Masood R., et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 137 (2005) 192
20. Tan M.H., and Chu T.M. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumor Biol 6 (1985) 89
21. Matsuo Y., Sawai H., Funahashi H., et al. Enhanced angiogenesis due to inflammatory cytokines from pancreatic cancer cell lines and relation to metastatic potential. Pancreas 28 (2004) 344
22. Bouvet M., Yang M., Nardin S., et al. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin Exp Metast 18 (2000) 213